Vioxx (rofecoxib) News and Research

RSS

Vioxx, also known as refecoxib, is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain in adults, and for the treatment of menstrual symptoms.

Vioxx was withdrawn from U.S. drugstores in September 2004 after a Merck study showed that long-term users of the drug had twice the risk of heart attack and stroke.

Appeals courts overturn two verdicts, judgment on award payment in Vioxx lawsuits

State appeals courts in New Jersey and Texas on Thursday reversed two jury verdicts and a judgment on payment of legal fees in lawsuits related to the COX-2 inhibitor Vioxx that would have required Merck to pay about $37 million, Bloomberg/Washington Post reports (Van Voris/Voreacos, Bloomberg/Washington Post, 5/30).

30 May 2008

Merck agrees to pay $58 million to aettle multistate lawsuit that claimed advertisements for Vioxx played down health risks

Merck on Tuesday agreed to a $58 million settlement with 29 states and the District of Columbia to end investigations over allegations that it downplayed cardiovascular risks caused by the COX-2 inhibitor Vioxx in direct-to-consumer advertisements dating back to 1999, the AP/Philadelphia Inquirer reports (Raffaele, AP/Philadelphia Inquirer, 5/21).

21 May 2008

Ibuprofen found to reduce the risk of Alzheimer's

A large study by scientists in the U.S. has revealed that the long-term use of ibuprofen may reduce the risk of a person developing Alzheimer's disease.

6 May 2008

New York Times examines opposition to proposed off-label promotion guidelines amid allegations of ghostwriting

The New York Times on Saturday examined how a recent report indicating that Merck used "ghostwriters" to produce medical journal articles in support of the COX-2 inhibitor Vioxx "has galvanized opponents to a federal proposal that would relax some restrictions on drug promotion" in the U.S.

21 Apr 2008

Sen. Grassley sends letter to Merck requesting explanation of recent JAMA reports

Sen. Chuck Grassley (R-Iowa) has sent a letter to Merck Chief Operating Officer Richard Clark requesting the company explain a recent report that found the company used employees or paid consultants rather than the physicians listed as lead authors to write several published studies of the COX-2 inhibitor Vioxx, CQ HealthBeat reports.

18 Apr 2008

Drug company coalition to push for looser rules on off-label marketing

Representatives of health care marketing firms, patient advocacy groups and pharmaceutical companies this week are in Washington, D.C., to express support for loosening rules regarding drug companies' ability to market medications for off-label uses, the Wall Street Journal reports (Mundy, Wall Street Journal, 4/18).

18 Apr 2008

Study shows how ignorance can be influential

In the current issue of The RAND Journal of Economics, USC researchers provide a challenge to the classic economic model of information manipulation, in which knowing more than anybody else is the key to influence.

25 Mar 2008

Risks of CVD for COX-2 inhibitors lower than previously reported

In an article published in the March issue of the Journal of Cardiovascular Pharmacology and Therapeutics, researchers from Florida Atlantic University (FAU) assess the totality of evidence, including strengths and limitations of different types of evidence contributing to the debate about cardiovascular disease (CVD) risks of cyclooxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).

27 Feb 2008

Merck to pay over $650 million for fraudulent price reporting and kickbacks claims

Merck & Company has agreed to pay more than $650 million to resolve allegations that the pharmaceutical manufacturer failed to pay proper rebates to Medicaid and other government health care programs and paid illegal remuneration to health care providers to induce them to prescribe the company's products, the Justice Department has announced.

8 Feb 2008

USA Today examines possible reasons for five-year low of FDA drug approval rate

USA Today on Monday examined how some pharmaceutical industry analysts cite "more cautious regulators and less innovation by drug makers" as reasons for the low rate of new drug approvals in 2007 (Schmit, USA Today, 2/4).

4 Feb 2008

Celebrex may disrupt heart rhythm

Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.

25 Jan 2008

Early warning for anti-smoking drug Chantix

The drug watchdog in the United States, the Food and Drug Administration (FDA), has expressed concerns regarding the anti-smoking drug Chantix.

21 Nov 2007

Pfizer wins day in court over Celebrex

Drug giant Pfizer has won a court ruling in the United States which could limit the lawsuits the company might possibly face over claims that its painkiller Celebrex caused heart attacks and strokes.

20 Nov 2007

Petition aims to stem the flood of dangerous drugs reaching Americans

In a petition filed with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.

15 Nov 2007